The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trends in the use of adjuvant anthracycline- and taxane-based chemotherapy regimens in early-stage breast cancer, by surgery type.
Shuling Li
No relevant relationships to disclose
Anne Hudson Blaes
No relevant relationships to disclose
Jiannong Liu
No relevant relationships to disclose
Yan Hu
No relevant relationships to disclose
Rohini Khorana Hernandez
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Scott Stryker
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Alexander Liede
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Allan J Collins
Consultant or Advisory Role - Amgen